News and Press Releases
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only...
Category: Other, Pharmaceutical
Posted: December 11, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from the GMMG-HD7...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2024
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 7, 2024
Sanofi launches high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK
Developed with a higher antigen content to increase protection in older adults, a population at greater risk of severe complications from infection. Now available and can be pre-ordered for the...
Category: Pharmaceutical
Posted: October 17, 2024
Sanofi and Orano join forces to develop next-generation radioligand medicines
17 October 2024 -- Paris, France -- Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024
Scotland first in the UK to recommend a new treatment option for lung cancer, which could help lower the risk of cancer returning
7 October 2024 -- Scotland, UK -- the Scottish Medicines Consortium has recommended MSD's KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC)...
Category: Other, Pharmaceutical
Posted: October 7, 2024
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 20, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk of disease progression or death...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 20, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit with 31% reduction in exacerbations along with lung function improvement Data from these two phase 3 studies supported...
Category: Clinical Trials, Drug Delivery, Pharmaceutical
Posted: September 10, 2024
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
26 August, 2024 – New Jersey, US – Merck, known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in...
Category: Pharmaceutical
Posted: August 28, 2024
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
European Commission Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years European Marketing Authorization based on positive overall survival and...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 28, 2024
Sartorius Collaborates with Sanofi to Commercialise End-To-End Platform for Downstream Process Intensification
Sartorius selected as preferred partner for development and commercialisation of integrated and continuous biomanufacturing (ICB) platform Modular platform will combine highest flexibility with standardisation ICB supports lower resource consumption and...
Category: BioManufacturing, Pharmaceutical
Posted: May 13, 2024
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Collaboration will harness Medidata Electronic Clinical Outcome Assessment (eCOA) for remote patient engagement and real-time data capture 6 February 2024 -- New York, US -- Medidata, a Dassault Systèmes company...
Category: Clinical Trials
Posted: February 7, 2024
European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma · First Significant Improvement in Overall Survival in Two Decades...
Category: Pharmaceutical
Posted: October 23, 2023
